Skip to main content
Top
Published in: Clinical Pharmacokinetics 10/2006

01-10-2006 | Leading Article

Ethnic or Racial Differences Revisited

Impact of Dosage Regimen and Dosage Form on Pharmacokinetics and Pharmacodynamics

Author: Dr Mei-Ling Chen

Published in: Clinical Pharmacokinetics | Issue 10/2006

Login to get access

Abstract

Ethnic or racial differences in pharmacokinetics and pharmacodynamics have been attributed to the distinctions in the genetic, physiological and pathological factors between ethnic/racial groups. These pharmacokinetic/pharmacodynamic differences are also known to be influenced by several extrinsic factors such as socioeconomic background, culture, diet and environment. However, it is noted that other factors related to dosage regimen and dosage form have largely been ignored or overlooked when conducting or analysing pharmacokinetic/pharmacodynamic studies in relation to ethnicity/race. Potential interactions can arise between the characteristics of ethnicity/race and a unique feature of dosage regimen or dosage form used in the study, which may partly account for the observed pharmacokinetic/pharmacodynamic differences between ethnic/racial groups.
Ethnic/racial differences in pharmacokinetics/pharmacodynamics can occur from drug administration through a specific route that imparts distinct pattern of absorption, distribution, transport, metabolism or excretion. For example, racial differences in the first-pass metabolism of a drug following oral administration may not be relevant when the drug is applied to the skin. On the other hand, ethnic/racial difference in pharmacokinetics/pharmacodynamics can also happen via two different routes of drug delivery, with varying levels of dissimilarity between routes. For example, greater ethnic/racial differences were observed in oral clearance than in systemic clearance of some drugs, which might be explained by the pre-systemic factors involved in the oral administration as opposed to the intravenous administration. Similarly, changes in the dose frequency and/or duration may have profound impact on the ethnic/racial differences in pharmacokinetic/pharmacodynamic outcome. Saturation of enzymes, transporters or receptors at high drug concentrations is a possible reason for many observed ethnic/racial discrepancies between single- and multiple-dose regimens, or between low- and high-dose administrations. The presence of genetic polymorphism of enzymes and/or transporters can further complicate the analysis of pharmacokinetic/pharmacodynamic data in ethnic/racial populations. Even within the same dosage regimen, the use of different dosage forms may trigger significantly different pharmacokinetic/pharmacodynamic responses in various ethnic/racial groups, given that different dosage forms may exhibit different rates of drug release, may release the drug at different sites, and/or have different retention times at specific sites of the body. It is thus cautioned that the pharmacokinetic/pharmacodynamic data obtained from different ethnic/racial groups cannot be indiscriminately compared or combined for analysis if there is a lack of homogeneity in the apparent ‘extrinsic’ factors, including dosage regimen and dosage form.
Literature
1.
go back to reference Wood AJJ, Zhou HH. Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet 1991; 20: 350–73PubMedCrossRef Wood AJJ, Zhou HH. Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet 1991; 20: 350–73PubMedCrossRef
3.
go back to reference Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation: current state knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995; 29: 192–209PubMedCrossRef Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation: current state knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995; 29: 192–209PubMedCrossRef
4.
go back to reference Johnson JA. Influence of race or ethnicity on pharmacokinetics of drugs. J Pharm Sci 1997; 86: 1328–33PubMedCrossRef Johnson JA. Influence of race or ethnicity on pharmacokinetics of drugs. J Pharm Sci 1997; 86: 1328–33PubMedCrossRef
5.
go back to reference Johnson JA. Predictability of the effects of race or ethnicity on pharmacokinetics of drugs. Int J Clin Pharmacol Ther 2000; 38: 53–60PubMed Johnson JA. Predictability of the effects of race or ethnicity on pharmacokinetics of drugs. Int J Clin Pharmacol Ther 2000; 38: 53–60PubMed
6.
go back to reference Poolsup N, Po A, Knight TL. Pharmacogenetics and psychopharmacotherapy. Int J Clin Pharmacol Ther 2000; 25: 197–220CrossRef Poolsup N, Po A, Knight TL. Pharmacogenetics and psychopharmacotherapy. Int J Clin Pharmacol Ther 2000; 25: 197–220CrossRef
7.
go back to reference Deierhoi MH, Haug III M. Review of select transplant subpopulations at high risk of failure from standard immunosuppressive therapy. Clin Transplant 2000; 14: 439–48PubMedCrossRef Deierhoi MH, Haug III M. Review of select transplant subpopulations at high risk of failure from standard immunosuppressive therapy. Clin Transplant 2000; 14: 439–48PubMedCrossRef
8.
go back to reference Xie H, Kim RB, Wood AJJ, et al. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001; 41: 815–50PubMedCrossRef Xie H, Kim RB, Wood AJJ, et al. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001; 41: 815–50PubMedCrossRef
9.
go back to reference Lin KM. Biological differences in depression and anxiety across races and ethnic groups. J Clin Psychiatry 2001; 62 Suppl. 13: 13–9PubMed Lin KM. Biological differences in depression and anxiety across races and ethnic groups. J Clin Psychiatry 2001; 62 Suppl. 13: 13–9PubMed
10.
go back to reference Desta Z, Zhou X, Shin J, et al. Clinical significance of the Cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41: 913–58PubMedCrossRef Desta Z, Zhou X, Shin J, et al. Clinical significance of the Cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 2002; 41: 913–58PubMedCrossRef
11.
go back to reference Bjornsson TD, Wagner JA, Donahue SR, et al. A review and assessment of potential sources of ethnic difference in drug responsiveness. J Clin Pharmacol 2003; 43: 943–67PubMedCrossRef Bjornsson TD, Wagner JA, Donahue SR, et al. A review and assessment of potential sources of ethnic difference in drug responsiveness. J Clin Pharmacol 2003; 43: 943–67PubMedCrossRef
12.
go back to reference Schaefer BM, Caracciolo V, Frishman WH, et al. Gender, ethnicity and genetics in cardiovascular disease. Part 1: basic principles. Heart Dis 2003; 5: 129–43PubMedCrossRef Schaefer BM, Caracciolo V, Frishman WH, et al. Gender, ethnicity and genetics in cardiovascular disease. Part 1: basic principles. Heart Dis 2003; 5: 129–43PubMedCrossRef
13.
go back to reference Kim K, Johnson JA, Derendorf H. Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol 2004; 44: 1083–105PubMedCrossRef Kim K, Johnson JA, Derendorf H. Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol 2004; 44: 1083–105PubMedCrossRef
14.
go back to reference Dirks NL, Huth B, Yates CR, et al. Pharmacokinetics of immunosuppressants: a perspective on ethnic differences. Int J Clin Pharmacol Ther 2004; 42: 701–18PubMed Dirks NL, Huth B, Yates CR, et al. Pharmacokinetics of immunosuppressants: a perspective on ethnic differences. Int J Clin Pharmacol Ther 2004; 42: 701–18PubMed
15.
go back to reference Anderson GD. Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. J Womens Health 2005; 14: 19–29CrossRef Anderson GD. Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. J Womens Health 2005; 14: 19–29CrossRef
16.
go back to reference Donovan MD. Sex and racial differences in pharmacological response: effect of route of administration and drug delivery system on pharmacokinetics. J Womens Health 2005; 14: 30–7CrossRef Donovan MD. Sex and racial differences in pharmacological response: effect of route of administration and drug delivery system on pharmacokinetics. J Womens Health 2005; 14: 30–7CrossRef
17.
go back to reference Chowbay B, Zhou S, Lee EJD. An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: experience in Singapore. Drug Metab Rev 2005; 37: 327–78PubMed Chowbay B, Zhou S, Lee EJD. An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: experience in Singapore. Drug Metab Rev 2005; 37: 327–78PubMed
18.
go back to reference International Conference on Harmonization Steering Committee. Guidance on ethnic factors in the acceptability of foreign clinical data. Fed Regist 1998; 63: 31790–6 International Conference on Harmonization Steering Committee. Guidance on ethnic factors in the acceptability of foreign clinical data. Fed Regist 1998; 63: 31790–6
19.
go back to reference Berardesca E, Maibach H. Racial differences in skin pathophysiology. J Am Acad Dermatol 1996; 34: 667–72PubMedCrossRef Berardesca E, Maibach H. Racial differences in skin pathophysiology. J Am Acad Dermatol 1996; 34: 667–72PubMedCrossRef
20.
go back to reference Kompaore F, Marty JP, Dupont C. In vivo evaluation of the stratum corneum barrier in blacks, Caucasians and Asians with two noninvasive methods. Skin Pharmacol 1993; 6: 200–7PubMedCrossRef Kompaore F, Marty JP, Dupont C. In vivo evaluation of the stratum corneum barrier in blacks, Caucasians and Asians with two noninvasive methods. Skin Pharmacol 1993; 6: 200–7PubMedCrossRef
21.
go back to reference Lin KM, Lau JK, Smith R, et al. Comparison of alprazolam plasma levels in normal Asians and Caucasian male volunteers. Psychopharmacology (Berl) 1988; 96: 365–9CrossRef Lin KM, Lau JK, Smith R, et al. Comparison of alprazolam plasma levels in normal Asians and Caucasian male volunteers. Psychopharmacology (Berl) 1988; 96: 365–9CrossRef
22.
go back to reference Lin KM, Poland RE, Lau JK, et al. Haloperidol and prolactin concentrations in Asians and Caucasians. J Clin Psychopharmacol 1988; 8: 195–201PubMedCrossRef Lin KM, Poland RE, Lau JK, et al. Haloperidol and prolactin concentrations in Asians and Caucasians. J Clin Psychopharmacol 1988; 8: 195–201PubMedCrossRef
23.
go back to reference Sowinski KM, Lima JJ, Burlew BS, et al. Racial differences in propranolol enantiomer kinetics following simultaneous i.v. and oral administration. Br J Clin Pharmacol 1996; 42: 339–46PubMedCrossRef Sowinski KM, Lima JJ, Burlew BS, et al. Racial differences in propranolol enantiomer kinetics following simultaneous i.v. and oral administration. Br J Clin Pharmacol 1996; 42: 339–46PubMedCrossRef
24.
go back to reference Johnson JA, Herring VL, Wolfe MS, et al. CYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differences. J Pharmacol Exp Ther 2000; 294: 1099–105PubMed Johnson JA, Herring VL, Wolfe MS, et al. CYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differences. J Pharmacol Exp Ther 2000; 294: 1099–105PubMed
25.
go back to reference Clegg LX, Li FP, Hankey BF, et al. Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) program population-based study. Arch Intern Med 2002; 162: 1985–93PubMedCrossRef Clegg LX, Li FP, Hankey BF, et al. Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) program population-based study. Arch Intern Med 2002; 162: 1985–93PubMedCrossRef
26.
27.
go back to reference Hershman D, Weinberg M, Rosner Z, et al. Ethnic neutropenia delay in African American women undergoing chemotherapy for early-stage breast cancer. J Natl Cancer Inst 2003; 95: 1545–8PubMedCrossRef Hershman D, Weinberg M, Rosner Z, et al. Ethnic neutropenia delay in African American women undergoing chemotherapy for early-stage breast cancer. J Natl Cancer Inst 2003; 95: 1545–8PubMedCrossRef
28.
go back to reference Bunke M, Sloan R, Brier M, et al. An improved glomerular filtration rate in cardiac transplant recipients with once-a-day cyclosporine dosing. Transplant 1995; 59: 537–40 Bunke M, Sloan R, Brier M, et al. An improved glomerular filtration rate in cardiac transplant recipients with once-a-day cyclosporine dosing. Transplant 1995; 59: 537–40
29.
go back to reference Tarantino A, Passerini P, Campise M, et al. Is cyclosporine in renal-transplant recipients more effective when given twice a day than in a single daily dose? Clin Transplant 2004; 78: 675–80 Tarantino A, Passerini P, Campise M, et al. Is cyclosporine in renal-transplant recipients more effective when given twice a day than in a single daily dose? Clin Transplant 2004; 78: 675–80
30.
go back to reference Siddoway LA, Thompson KA, McAllister B, et al. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 1987; 75: 785–91PubMedCrossRef Siddoway LA, Thompson KA, McAllister B, et al. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 1987; 75: 785–91PubMedCrossRef
31.
go back to reference Brosen K. Recent development in hepatic drug oxidation: implications for clinical pharmacokinetics. Clin Pharmacokinet 1990; 18: 220–39PubMedCrossRef Brosen K. Recent development in hepatic drug oxidation: implications for clinical pharmacokinetics. Clin Pharmacokinet 1990; 18: 220–39PubMedCrossRef
32.
go back to reference Andersson T, Cederberg C, Heggelund A, et al. The pharmacokinetics of single and repeated once-daily dose of 10, 20 and 40mg omeprazole as enteric-coated granules. Drug Invest 1991; 3: 45–52CrossRef Andersson T, Cederberg C, Heggelund A, et al. The pharmacokinetics of single and repeated once-daily dose of 10, 20 and 40mg omeprazole as enteric-coated granules. Drug Invest 1991; 3: 45–52CrossRef
33.
go back to reference Sindrup SH, Brosen K, Gram LF, et al. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992; 51: 278–87PubMedCrossRef Sindrup SH, Brosen K, Gram LF, et al. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992; 51: 278–87PubMedCrossRef
34.
go back to reference Funck-Brentano C, Becquemont L, Kroemer HK, et al. Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone. Clin Pharmacol Ther 1994; 55: 256–69PubMedCrossRef Funck-Brentano C, Becquemont L, Kroemer HK, et al. Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone. Clin Pharmacol Ther 1994; 55: 256–69PubMedCrossRef
35.
go back to reference Andersson T, Hassan-Alin M, Hasselgren G, et al. Pharmacokinetic studies with esomeprazole, the (s) isomer of omeprazole. Clin Pharmacokinet 2001; 40: 411–26PubMedCrossRef Andersson T, Hassan-Alin M, Hasselgren G, et al. Pharmacokinetic studies with esomeprazole, the (s) isomer of omeprazole. Clin Pharmacokinet 2001; 40: 411–26PubMedCrossRef
36.
go back to reference Roh H, Chung J, Oh D, et al. Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. Br J Clin Pharmacol 2001; 52: 265–71PubMedCrossRef Roh H, Chung J, Oh D, et al. Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. Br J Clin Pharmacol 2001; 52: 265–71PubMedCrossRef
37.
go back to reference Zhang-Wang J, Beiser M, Zipursky RB, et al. An investigation of ethnic and gender differences in the pharmacodynamics of haloperidol. Psychiatry Res 1998; 81: 333–9CrossRef Zhang-Wang J, Beiser M, Zipursky RB, et al. An investigation of ethnic and gender differences in the pharmacodynamics of haloperidol. Psychiatry Res 1998; 81: 333–9CrossRef
38.
go back to reference Lin KM, Poland RE, Nuccio I, et al. A longitudinal assessment of haloperidol doses and serum concentrations in Asian and Caucasian schizophrenic patients. Am J Psychiatry 1989; 146: 1307–11PubMed Lin KM, Poland RE, Nuccio I, et al. A longitudinal assessment of haloperidol doses and serum concentrations in Asian and Caucasian schizophrenic patients. Am J Psychiatry 1989; 146: 1307–11PubMed
39.
go back to reference Grant DM, Tang BK, Kalow W. Variability in caffeine metabolism. Clin Pharmacol Ther 1983; 33: 591–602PubMedCrossRef Grant DM, Tang BK, Kalow W. Variability in caffeine metabolism. Clin Pharmacol Ther 1983; 33: 591–602PubMedCrossRef
40.
go back to reference Kalow W, Tang BK. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 1991; 50: 508–19PubMedCrossRef Kalow W, Tang BK. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 1991; 50: 508–19PubMedCrossRef
41.
go back to reference Caraco Y, Lagerstrom P, Wood AJJ. Ethnic and genetic determinants of omeprazole disposition and effect. Clin Pharmacol Ther 1996; 60: 157–67PubMedCrossRef Caraco Y, Lagerstrom P, Wood AJJ. Ethnic and genetic determinants of omeprazole disposition and effect. Clin Pharmacol Ther 1996; 60: 157–67PubMedCrossRef
42.
go back to reference Andersson T, Regardh CG, Lou YC, et al. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992; 2: 25–31PubMedCrossRef Andersson T, Regardh CG, Lou YC, et al. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992; 2: 25–31PubMedCrossRef
43.
go back to reference Kim RB. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev 2002; 34: 47–54PubMedCrossRef Kim RB. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev 2002; 34: 47–54PubMedCrossRef
44.
go back to reference Kroetz DL, Pauli-Magnus C, Hodges LM, et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003; 13: 481–94PubMedCrossRef Kroetz DL, Pauli-Magnus C, Hodges LM, et al. Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003; 13: 481–94PubMedCrossRef
45.
go back to reference Marzolini C, Paus E, Buclin T, et al. Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance. Clin Pharmacol Ther 2004; 75: 13–33PubMedCrossRef Marzolini C, Paus E, Buclin T, et al. Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance. Clin Pharmacol Ther 2004; 75: 13–33PubMedCrossRef
46.
go back to reference Pauli-Magnus C, Kroetz DL. Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1). Pharm Res 2004; 21: 904–13PubMedCrossRef Pauli-Magnus C, Kroetz DL. Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1). Pharm Res 2004; 21: 904–13PubMedCrossRef
47.
go back to reference Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 2005; 78: 260–77PubMedCrossRef Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 2005; 78: 260–77PubMedCrossRef
48.
go back to reference Andersson T, Flockhart DA, Goldstein DB, et al. Drug-metabolizing enzymes: Evidence for clinical utility of pharmacogenomic tests. Clin Pharmacol Ther 2005; 78: 559–81PubMedCrossRef Andersson T, Flockhart DA, Goldstein DB, et al. Drug-metabolizing enzymes: Evidence for clinical utility of pharmacogenomic tests. Clin Pharmacol Ther 2005; 78: 559–81PubMedCrossRef
49.
go back to reference Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000; 97: 3473–8PubMedCrossRef Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000; 97: 3473–8PubMedCrossRef
50.
go back to reference Vertuyft C, Schwab M, Schaeffeler E, et al. Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol 2003; 58: 809–12 Vertuyft C, Schwab M, Schaeffeler E, et al. Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol 2003; 58: 809–12
51.
go back to reference Johne A, Kopke K, Gerloff T, et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 2002; 72: 584–94PubMedCrossRef Johne A, Kopke K, Gerloff T, et al. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 2002; 72: 584–94PubMedCrossRef
52.
go back to reference Kurata Y, Leiri I, Kimura M, et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 2002; 72: 209–19PubMedCrossRef Kurata Y, Leiri I, Kimura M, et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 2002; 72: 209–19PubMedCrossRef
53.
go back to reference Horinouchi M, Sakaeda T, Nakamura T, et al. Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin. Pharm Res 2002; 19: 1581–5PubMedCrossRef Horinouchi M, Sakaeda T, Nakamura T, et al. Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin. Pharm Res 2002; 19: 1581–5PubMedCrossRef
54.
go back to reference Sakaeda T, Nakamura T, Horinouchi M, et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 2001; 18: 1400–4PubMedCrossRef Sakaeda T, Nakamura T, Horinouchi M, et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 2001; 18: 1400–4PubMedCrossRef
55.
go back to reference Becquemont L, Verstuyft C, Kerb R, et al. Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin Pharmacol Ther 2001; 70: 317–26 Becquemont L, Verstuyft C, Kerb R, et al. Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin Pharmacol Ther 2001; 70: 317–26
56.
go back to reference Gerloff T, Schaeffer M, Johne A, et al. MDR genotypes do not influence the absorption of a single oral dose of 1mg digoxin in healthy white males. Br J Clin Pharmacol 2002; 54: 610–6PubMedCrossRef Gerloff T, Schaeffer M, Johne A, et al. MDR genotypes do not influence the absorption of a single oral dose of 1mg digoxin in healthy white males. Br J Clin Pharmacol 2002; 54: 610–6PubMedCrossRef
57.
go back to reference Castaneda-Hernandez G, Hoyo-Vadillo C, Herrera JE. Differences in nifedipine concentration-effect relationship between capsule and slow release tablet administration. Int J Clin Pharmacol Ther 1995; 33: 56–60PubMed Castaneda-Hernandez G, Hoyo-Vadillo C, Herrera JE. Differences in nifedipine concentration-effect relationship between capsule and slow release tablet administration. Int J Clin Pharmacol Ther 1995; 33: 56–60PubMed
58.
go back to reference Kleinbloesem GH, von Brummelen P, Faber H, et al. Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man. Biochem Pharmacol 1984; 33: 3721–4PubMedCrossRef Kleinbloesem GH, von Brummelen P, Faber H, et al. Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man. Biochem Pharmacol 1984; 33: 3721–4PubMedCrossRef
59.
go back to reference Lobo J, Jack DB, Kendall MJ. The intra- and inter-subject variability of nifedipine pharmacokinetics in young volunteers. Eur J Clin Pharmacol 1986; 30: 57–60PubMedCrossRef Lobo J, Jack DB, Kendall MJ. The intra- and inter-subject variability of nifedipine pharmacokinetics in young volunteers. Eur J Clin Pharmacol 1986; 30: 57–60PubMedCrossRef
60.
go back to reference Beerahee M, Wilkins MR, Jack DB, et al. Twelve hour (trough) plasma nifedipine concentrations during chronic treatment with Nifedipine Retard. Eur J Clin Pharmacol 1987; 32: 347–9PubMedCrossRef Beerahee M, Wilkins MR, Jack DB, et al. Twelve hour (trough) plasma nifedipine concentrations during chronic treatment with Nifedipine Retard. Eur J Clin Pharmacol 1987; 32: 347–9PubMedCrossRef
61.
go back to reference Renwick AG, Robertson DRC, Macklin B, et al. The pharmacokinetics of oral nifedipine: a population study. Br J Clin Pharmacol 1988; 25: 701–8PubMedCrossRef Renwick AG, Robertson DRC, Macklin B, et al. The pharmacokinetics of oral nifedipine: a population study. Br J Clin Pharmacol 1988; 25: 701–8PubMedCrossRef
62.
go back to reference Schellens JHM, Soons PA, Breimer DD. Lack of bimodality in nifedipine plasma kinetics in a larger population of healthy subjects. Biochem Pharmacol 1988; 37: 2507–10PubMedCrossRef Schellens JHM, Soons PA, Breimer DD. Lack of bimodality in nifedipine plasma kinetics in a larger population of healthy subjects. Biochem Pharmacol 1988; 37: 2507–10PubMedCrossRef
63.
go back to reference Hoyo-Vadillo C, Castaneda-Hernandez G, Herrera JE, et al. Pharmacokinetics of oral nifedipine: relevance of the distribution phase. J Clin Pharmacol 1989; 29: 251–6PubMed Hoyo-Vadillo C, Castaneda-Hernandez G, Herrera JE, et al. Pharmacokinetics of oral nifedipine: relevance of the distribution phase. J Clin Pharmacol 1989; 29: 251–6PubMed
64.
go back to reference Hoyo-Vadillo C, Castaneda-Hernandez G, Herrera JE, et al. Pharmacokinetics of nifedipine slow release tablet in Mexican subjects: further evidence for an oxidation polymorphism. J Clin Pharmacol 1989; 29: 816–20PubMed Hoyo-Vadillo C, Castaneda-Hernandez G, Herrera JE, et al. Pharmacokinetics of nifedipine slow release tablet in Mexican subjects: further evidence for an oxidation polymorphism. J Clin Pharmacol 1989; 29: 816–20PubMed
65.
go back to reference Ahsan CH, Renwick AG, Macklin B, et al. Ethnic differences in the pharmacokinetics of oral nifedipine. Br J Clin Pharmacol 1991; 31: 399–403PubMedCrossRef Ahsan CH, Renwick AG, Macklin B, et al. Ethnic differences in the pharmacokinetics of oral nifedipine. Br J Clin Pharmacol 1991; 31: 399–403PubMedCrossRef
66.
go back to reference Castaneda-Hernandez G, Hoyo-Vadillo C, Palma-Aguirre JA, et al. Pharmacokinetics of oral nifedipine in different populations. J Clin Pharmacol 1992; 32: 140–5 Castaneda-Hernandez G, Hoyo-Vadillo C, Palma-Aguirre JA, et al. Pharmacokinetics of oral nifedipine in different populations. J Clin Pharmacol 1992; 32: 140–5
67.
go back to reference Ahsan CH, Renwick AG, Waller DG, et al. The influences of dose and ethnic origins on the pharmacokinetics of nifedipine. Clin Pharmacol Ther 1993; 54: 329–38PubMedCrossRef Ahsan CH, Renwick AG, Waller DG, et al. The influences of dose and ethnic origins on the pharmacokinetics of nifedipine. Clin Pharmacol Ther 1993; 54: 329–38PubMedCrossRef
68.
go back to reference Davies GJ, Growder M, Reid B, et al. Bowel function measurements of individuals with different eating patterns. Gut 1986; 27: 164–9PubMedCrossRef Davies GJ, Growder M, Reid B, et al. Bowel function measurements of individuals with different eating patterns. Gut 1986; 27: 164–9PubMedCrossRef
69.
go back to reference Prescott LF, Yoovathaworn K, Makarananda K, et al. Impaired absorption of paracetamol in vegetarians. Br J Clin Pharmacol 1993; 36: 237–40PubMedCrossRef Prescott LF, Yoovathaworn K, Makarananda K, et al. Impaired absorption of paracetamol in vegetarians. Br J Clin Pharmacol 1993; 36: 237–40PubMedCrossRef
70.
go back to reference Chen M-L. Confounding factors for sex differences in pharmacokinetics and pharmacodynamics: focus on dosing regimen, dosage form, and formulation. Clin Pharmacol Ther 2005; 78: 322–9PubMedCrossRef Chen M-L. Confounding factors for sex differences in pharmacokinetics and pharmacodynamics: focus on dosing regimen, dosage form, and formulation. Clin Pharmacol Ther 2005; 78: 322–9PubMedCrossRef
71.
go back to reference Muck W, Unger S, Kawano K, et al. Inter-ethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Br J Clin Pharmacol 1998; 45(6): 583–90PubMedCrossRef Muck W, Unger S, Kawano K, et al. Inter-ethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin. Br J Clin Pharmacol 1998; 45(6): 583–90PubMedCrossRef
72.
go back to reference Shimoda K, Jerling M, Bottiger Y, et al. Pronounced differences in the disposition of clomipramine between Japanese and Swedish patients. J Clin Psychopharmacol 1999; 19(5): 393–400PubMedCrossRef Shimoda K, Jerling M, Bottiger Y, et al. Pronounced differences in the disposition of clomipramine between Japanese and Swedish patients. J Clin Psychopharmacol 1999; 19(5): 393–400PubMedCrossRef
73.
go back to reference Krecic-Shepard ME, Park K, Barnas C, et al. Race and sex influence clearance of nifedipine: results of a population study. Clin Pharmacol Ther 2000; 68: 130–42PubMedCrossRef Krecic-Shepard ME, Park K, Barnas C, et al. Race and sex influence clearance of nifedipine: results of a population study. Clin Pharmacol Ther 2000; 68: 130–42PubMedCrossRef
74.
go back to reference Kang D, Verotta D, Krecic-Shepard ME, et al. Population analysis of sustained-release verapamil in patients: effects of sex, race, and smoking. Clin Pharmacol Ther 2003; 73: 31–40PubMedCrossRef Kang D, Verotta D, Krecic-Shepard ME, et al. Population analysis of sustained-release verapamil in patients: effects of sex, race, and smoking. Clin Pharmacol Ther 2003; 73: 31–40PubMedCrossRef
75.
go back to reference Tatami S, Yamamura N, Sarashina A, et al. Pharmacokinetic comparison of an angiotensin II receptor antagonist, telmisartan, in Japanese and western hypertensive patients using population pharmacokinetic method. Drug Metab Pharmacokinet 2004; 19: 15–23PubMedCrossRef Tatami S, Yamamura N, Sarashina A, et al. Pharmacokinetic comparison of an angiotensin II receptor antagonist, telmisartan, in Japanese and western hypertensive patients using population pharmacokinetic method. Drug Metab Pharmacokinet 2004; 19: 15–23PubMedCrossRef
Metadata
Title
Ethnic or Racial Differences Revisited
Impact of Dosage Regimen and Dosage Form on Pharmacokinetics and Pharmacodynamics
Author
Dr Mei-Ling Chen
Publication date
01-10-2006
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 10/2006
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.2165/00003088-200645100-00001

Other articles of this Issue 10/2006

Clinical Pharmacokinetics 10/2006 Go to the issue

Review Article

Nanomedicine